221 Development of abatacept- and adalimumab-specific predictive models of response to therapy in rheumatoid arthritis using data from a head-to-head study
Clicks: 248
ID: 116722
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
248 views
39 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #3 of 6 articles by views in rheumatology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background: Highly effective, targeted DMARD therapies with different mechanisms of action are available for RA. Translating precision medicine into clinical pr
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (21 words).
Try re-searching for a better abstract.
| Reference Key |
somnath2018rheumatology221 development
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Bandyopadhyay, Somnath;Maldonado, Michael A;Ammar, Ron;Schiff, Michael;Weinblatt, Michael;Fleischmann, Roy;Connolly, Sean E; |
| Journal | rheumatology |
| Year | 2018 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.